Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 10/20 | 0.47 |
| ▸ | MMP2 | P08253 | 10/20 | 0.47 |
| ▸ | MMP3 | P08254 | 9/20 | 0.47 |
| ▸ | PDE4A | P27815 | 8/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.47 |
| ▸ | MMP13 | P45452 | 3/20 | 0.47 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | BMP1 | P13497 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7453483 | 0.90 | ALDH1A1 (0.38) | MMP1MMP2MMP3PDE4APDE4B | |
| SCHEMBL2582026 | 0.88 | ESR1 (0.36) | MMP1MMP2MMP3PDE4APDE4B | |
| SCHEMBL7453537 | 0.87 | PRMT1 (0.37) | MMP1MMP2MMP3PDE4APDE4B | |
| SCHEMBL7459208 | 0.87 | POLB (0.38) | MMP1MMP2MMP3MMP13MMP9 | |
| SCHEMBL8024734 | 0.87 | PRMT1 (0.37) | MMP1MMP2MMP3PDE4APDE4B | |
| SCHEMBL13673910 | 0.85 | MMP2 (0.43) | MMP2MMP3MMP13MMP9ALDH1A1 | |
| SCHEMBL2585365 | 0.84 | KMT2A (0.42) | MMP1MMP2MMP3MMP13MMP9 | |
| SCHEMBL7453235 | 0.82 | PRMT1 (0.40) | ALDH1A1POLB | |
| SCHEMBL7456132 | 0.80 | ALDH1A1 (0.48) | MMP1MMP2MMP3PDE4APDE4B | |
| SCHEMBL2578162 | 0.79 | CYP19A1 (0.42) | MMP1MMP2MMP13MMP9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020052399-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | VAZQUEZ MICHAEL L (US) | 2002-05-02 | — | — | US | claimed |
| US-RE43802-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-11-13 | — | — | US | disclosed |
| US-RE42889-E1 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2011-11-01 | — | — | US | disclosed |
| US-7141609-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-11-28 | — | — | US | disclosed |
| US-20050267171-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2005-12-01 | — | — | US | disclosed |
| US-6924286-B1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040044047-A1 | Alpha and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-03-04 | — | — | US | disclosed |
| US-20030191319-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2003-10-09 | — | — | US | disclosed |
| US-6417387-B1 | IN PARTICULAR AS INHIBITORS OF HIV PROTEASE. | G.D. SEARLE & CO. | 2002-07-09 | — | — | US | disclosed |
| US-20020052399-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | VAZQUEZ MICHAEL L (US) | 2002-05-02 | — | — | US | disclosed |
| US-6248775-B1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G. D. SEARLE & CO. | 2001-06-19 | — | — | US | disclosed |
| US-6046190-A | FOR INHIBITING RETROVIRAL PROTEASES SUCH AS HUMAN IMMUNODEFICIENCY VIRUS | G.D. SEARLE & CO. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5968942-A | INHIBITORS OF HIV PROTEASE | G. D. SEARLE & CO. (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0715618-B1 | HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1998-12-16 | — | — | EP | disclosed |
| WO-1995006030-A1 | HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052399-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | MMP1 844/4885MMP2 671/4885MMP3 397/4885 |
| US-20050267171-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | MMP1 810/4885MMP2 658/4885MMP3 350/4885 |
| US-20030191319-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | MMP1 844/4885MMP2 671/4885MMP3 397/4885 |
| US-20040044047-A1 | Alpha and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, PREP, ANPEP | MMP1 689/4885MMP2 491/4885MMP3 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.